Tema Etfs LLC Acquires 46,076 Shares of Cogent Biosciences, Inc. $COGT

Tema Etfs LLC raised its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT) by 64.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 117,639 shares of the technology company’s stock after acquiring an additional 46,076 shares during the quarter. Tema Etfs LLC’s holdings in Cogent Biosciences were worth $845,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in the stock. Candriam S.C.A. purchased a new stake in Cogent Biosciences during the 2nd quarter worth about $3,068,000. Goldman Sachs Group Inc. lifted its holdings in shares of Cogent Biosciences by 14.3% in the first quarter. Goldman Sachs Group Inc. now owns 988,962 shares of the technology company’s stock worth $5,924,000 after buying an additional 124,069 shares in the last quarter. F m Investments LLC purchased a new stake in shares of Cogent Biosciences in the second quarter worth about $862,000. Ensign Peak Advisors Inc boosted its position in shares of Cogent Biosciences by 162.0% in the second quarter. Ensign Peak Advisors Inc now owns 49,325 shares of the technology company’s stock valued at $354,000 after acquiring an additional 30,500 shares during the period. Finally, Exome Asset Management LLC bought a new stake in Cogent Biosciences during the 1st quarter worth approximately $3,724,000.

Cogent Biosciences Price Performance

Shares of NASDAQ:COGT opened at $38.77 on Friday. The company has a quick ratio of 6.38, a current ratio of 6.38 and a debt-to-equity ratio of 0.23. The stock has a market cap of $5.52 billion, a PE ratio of -23.64 and a beta of 0.50. The company’s fifty day moving average is $24.04 and its 200 day moving average is $14.88. Cogent Biosciences, Inc. has a 52 week low of $3.72 and a 52 week high of $41.27.

Cogent Biosciences (NASDAQ:COGT) last released its quarterly earnings data on Monday, November 3rd. The technology company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.04. Research analysts anticipate that Cogent Biosciences, Inc. will post -2.42 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Robert W. Baird upped their price target on shares of Cogent Biosciences from $14.00 to $34.00 and gave the stock a “neutral” rating in a report on Tuesday, November 11th. Guggenheim upped their target price on Cogent Biosciences from $17.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, August 25th. Wedbush upgraded Cogent Biosciences from a “neutral” rating to an “outperform” rating and set a $38.00 price target for the company in a research report on Monday, November 10th. JPMorgan Chase & Co. boosted their price objective on Cogent Biosciences from $30.00 to $44.00 and gave the stock an “overweight” rating in a report on Tuesday, October 21st. Finally, HC Wainwright raised their target price on shares of Cogent Biosciences from $21.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.33.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.